Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.

JW, Park; YJ, Kim; DY, Kim; SH, Bae; SW, Paik; YJ, Lee; HY, Kim; HC, Lee; SY, Han; JY, Cheong; OS, Kwon; JE, Yeon; BH, Kim; J, Hwang

doi:10.1016/j.jhep.2018.11.029

Public

Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.

Shared by NobleBlocks on Dec 6, 2018 • 12:00 AM UTC

Authors:

Park JW

Kim YJ

Kim DY

Abstract

<h4>Background & aims</h4>Sorafenib is first-line standard of care for patients with advanced hepatocellular carcinoma (HCC), yet it confers limited survival benefit. Therefore, we aimed to compare clinical outcomes of sorafenib combined with concurrent conventional transarterial chemoembolization (...

Subject

Hepatocellular carcinoma

Combination treatment

Sorafenib

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!